STOCK TITAN

Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Turning Point Therapeutics, Inc. (NASDAQ: TPTX) announced that President and CEO Athena Countouriotis, M.D., will participate in a Q&A session at the 42nd annual Goldman Sachs Healthcare Conference on June 9 at 1:20 p.m. ET. The session will be accessible via audio webcast on the company’s Investor page. Turning Point focuses on precision oncology, with investigational drugs targeting genetic drivers of cancer, including their lead candidate repotrectinib, currently in multiple clinical trials.

Positive
  • None.
Negative
  • None.

SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question-and-answer session at the 42nd annual Goldman Sachs Healthcare Conference on June 9.

Dr. Countouriotis’ session is scheduled to begin at 1:20 p.m. ET and will be accessible via audio webcast through the Investors page of www.tptherapeutics.com.

About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. Turning Point’s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point’s business and the other risks described in Turning Point Therapeutics’ filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact:
Jim Mazzola
jim.mazzola@tptherapeutics.com
858-342-8272


FAQ

What is Turning Point Therapeutics scheduled to present at the Goldman Sachs Healthcare Conference?

Turning Point Therapeutics will have Athena Countouriotis participate in a Q&A session on June 9 at 1:20 p.m. ET.

Where can I watch the Turning Point Therapeutics conference session?

You can access the audio webcast of the session on the Investors page of Turning Point Therapeutics' website.

What is the focus of Turning Point Therapeutics' drug development?

Turning Point Therapeutics focuses on precision oncology, developing therapies targeting genetic drivers of cancer.

What are the clinical trials available for Turning Point's lead drug candidate?

Repotrectinib, the lead candidate of Turning Point, is currently in a registrational Phase 2 study for adults and a Phase 1/2 study for pediatric patients.

What types of cancer does Turning Point Therapeutics aim to treat?

Turning Point Therapeutics aims to treat various cancers, including non-small cell lung cancer, through their next-generation therapies.

TPTX

NASDAQ:TPTX

TPTX Rankings

TPTX Latest News

TPTX Stock Data

3.81B
49.72M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link